PTAB challenges

Proceedings overview

One Post-Grant Review (PGR) proceeding has been filed against US patent 12280146. This single proceeding, PGR2026-00021, reached a status of Discretionary Denial. This outcome indicates that the patent has not been challenged on its merits through an AIA trial, providing a strong defensive posture for the patent owner, as the claims remain untested and valid.

PGR2026-00021 — Sun Pharmaceutical Industries, Inc. v. Montserrat FOGUET et al

• Type: Post-Grant Review
• Filed: 2026-01-16
• Status: Discretionary Denial. The Board declined to institute the PGR trial.
• Judge panel: Not publicly available from the provided data.
• Petition grounds: The petition challenged claims 1-20 of US12280146 under 35 U.S.C. §§ 102 and 103, based on various prior art references including US 2008/0176829 A1 (Kopff), US 2012/0329766 A1 (Hickerson), US 2013/0217686 A1 (Reinhold), and US 2019/0240212 A1 (Schauer).
• Institution decision: Denied on 2026-05-26. The Board exercised its discretion to deny institution under 35 U.S.C. § 314(a) based on factors derived from Fintiv and NHK Spring, considering a co-pending district court litigation. Specifically, the Board noted that a district court case, Biofrontera, Inc. v. Sun Pharmaceutical Industries, Inc., Case No. 1:26-cv-00001 (D. Del.), was filed on the same day as the PGR petition, raising similar invalidity contentions. The Board found that the petitioner had not demonstrated good cause to proceed with the PGR despite the advanced stage of the district court proceeding, applying the Fintiv factors.
• Final Written Decision: Not applicable; institution was denied.
• Settlement / termination: Not applicable; institution was denied.
• Appeal: Not applicable; institution was denied, and there is no Final Written Decision to appeal.
• Defensive value: The discretionary denial means that the claims of US12280146 have not been found unpatentable by the PTAB. This outcome strengthens the patent owner's position as it avoids an initial validity challenge, requiring any future challenges to present compelling arguments to overcome the discretionary denial precedent, or to challenge validity in a different forum.

Strategic summary

All claims (1-20) of US12280146 are currently UNTESTED at the PTAB, as the sole Post-Grant Review petition, PGR2026-00021, was discretionarily denied. No claims have been canceled or sustained by the PTAB. The patent therefore retains its full scope as granted.

Regarding the estoppel landscape, since the PGR was denied institution under Fintiv, the statutory estoppel provisions of 35 U.S.C. § 325(e)(2) do not apply. This means that Sun Pharmaceutical Industries, Inc. (and its privies) are not barred from raising the same or reasonably could have raised invalidity grounds in other proceedings, such as the co-pending district court litigation or a future IPR. This also implies that the prior art raised in the PGR petition (US 2008/0176829 A1, US 2012/0329766 A1, US 2013/0217686 A1, and US 2019/0240212 A1) is still available for use in other forums.

The pattern signal here is that the patent owner, Biofrontera Inc., successfully fended off the initial PTAB challenge through a discretionary denial strategy. The co-filing of district court litigation and the PGR petition by the petitioner, Sun Pharmaceutical, was a critical factor in the PTAB's decision, highlighting the increasing importance of coordinating litigation strategies between district court and PTAB proceedings. The petitioner, Unified Patents, listed for the litigation on Google Patents, indicates an entity focused on patent challenges, but the PTAB record shows Sun Pharmaceutical Industries, Inc. as the petitioner for PGR2026-00021.

Recommended next steps

For a defendant facing assertion of US12280146, the key takeaway is that the patent claims have not been validated or invalidated by the PTAB. The discretionary denial of PGR2026-00021, documented in the Institution Decision, means that the Board declined to institute the trial, rather than reaching a decision on the merits of the patentability challenge. The full details of the Board's reasoning for denying institution can be found in the institution decision for PGR2026-00021, available on the USPTO PTAB Decisions portal.

Given the Fintiv-based denial, a future PTAB challenge would need to carefully consider the status of any parallel district court litigation to avoid a similar discretionary denial. Alternatively, a defendant could pursue a validity challenge solely in district court. Since there are no active PTAB proceedings, there are no upcoming trial-stage milestones to monitor. The absence of an active AIA trial means the patent owner currently holds a position where their patent's validity has not been weakened by a PTAB challenge.